Heart failure & cardiomyopathies
Heart Failure, Chronic Obstructive Pulmonary Disease and Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from DELIVER
Authors' conclusion
Mild-to-moderate COPD is common in patients with HFmrEF/HFpEF and is associated with worse outcomes. The beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, regardless of COPD status.
Study context
- Population
- Patients with HFmrEF/HFpEF, by chronic obstructive pulmonary disease (COPD) status (severe pulmonary disease excluded)694 (11.1%) with COPD
- Participants
- 6,261 patients
- Comparison
- Dapagliflozin vs placebo, by COPD status
- Primary endpoint
- CV death or worsening HF
Methodological detailspre-specified analysis
- Pre-specified analysis
Primary result
As reported in the abstract
CV death or worsening HF, by COPD status (subgroups)
Dapagliflozin vs PlaceboHazard ratio (95% CI)P value
No COPD
0.82(0.72–0.93)
P = 0.98for interactionCOPD
0.82(0.62–1.10)
P = 0.98for interactionFurther findings
| Outcome | Adjusted HR (95% CI) | |
|---|---|---|
| CV death or worsening HF: mild-to-moderate COPDvs no COPD | 1.28 (1.08–1.51) | |
| 0.512Adjusted hazard ratio (log scale) |
HF, CV and all-cause hospitalization, deaths and composites
- Consistent effects irrespective of COPD status
KCCQ scores · baseline to 8 months
- Dapagliflozin improved KCCQ to a similar extent with and without mild-to-moderate COPD
- P for interaction ≥ 0.63
Safety
Adverse events and treatment discontinuation
- Not more frequent with dapagliflozin than placebo irrespective of COPD status
Original publication
Heart Failure, Chronic Obstructive Pulmonary Disease and Efficacy and Safety of Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from DELIVER. Eur J Heart Fail. Published 1 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →